Innovotech Reports Record Q3 2025 Revenue Driven by Diversified Technology Portfolio

Innovotech Inc. reported record revenues for its third quarter of 2025, generating $1,267,692 with net income of $92,945. The company's year-to-date performance shows $3,410,204 in total revenues, demonstrating sustained growth across its diversified technology portfolio. Several key factors contributed to this financial performance, including growing demand for antimicrobial contract research services, strong analytical services performance through its wholly-owned subsidiary Keystone Labs, and increased product sales.

CEO Craig Milne emphasized the strategic foundation behind these results, stating the company has been building multiple parallel efforts and investments to support expansion. The financial performance reflects the changes underway as Innovotech continues to develop its specialized laboratory services and biotechnology operations. The company's diversified approach appears to be paying dividends, with multiple revenue streams contributing to the record quarterly results.

Innovotech Labs Corporation, the company's contract research organization, provides proprietary devices for antimicrobial testing across multiple applications and commercializes antimicrobial silver solutions. More information about these services is available at https://www.innovotech.ca. Meanwhile, Keystone Labs Inc., serving the Canadian pharmaceutical industry and industrial markets, operates as a DEL-accredited laboratory with detailed services accessible at https://www.keystonelabs.ca.

The company's portfolio extends beyond laboratory services, with Innovotech holding a 60% stake in NouLifeSciences Inc., which maintains intellectual property related to antioxidant molecules. These molecules show potential applications in cosmetics and various medical conditions, including neuropathies, representing additional growth opportunities for the company. The diversified business model appears to be providing stability while allowing for expansion across multiple technology sectors.

While the company trades on the TSX Venture Exchange under the symbol IOT, investors should note that forward-looking statements are subject to various risks and uncertainties. These include regulatory environment challenges, currency fluctuations, reliance on a small number of customers including government organizations, operating result variability, and intellectual property protection concerns. The company's performance reflects its strategic positioning in specialized technology markets where demand for antimicrobial research and analytical services continues to show strength.